clinic
metagenom
nextgener
sequenc
mng
comprehens
analysi
microbi
host
genet
materi
dna
rna
sampl
patient
rapidli
move
research
clinic
laboratori
emerg
approach
chang
physician
diagnos
treat
infecti
diseas
applic
span
wide
rang
area
includ
antimicrobi
resist
microbiom
human
host
gene
express
transcriptom
oncolog
focu
challeng
implement
mng
clinic
laboratori
address
potenti
solut
maxim
impact
patient
care
public
health
field
clinic
microbiolog
compris
diagnost
microbiolog
identif
patho
gen
clinic
sampl
guid
manag
treatment
strategi
patient
infect
public
health
microbiolog
surveil
moni
tore
infecti
diseas
outbreak
commun
tradit
diagnost
techniqu
microbiolog
laboratori
includ
growth
isol
micro
organ
cultur
detect
pathogen
specif
anti
bodi
serolog
antigen
molecular
identi
ficat
microbi
nucleic
acid
dna
rna
commonli
via
pcr
molecular
assay
target
limit
number
pathogen
use
specif
prim
er
probe
metagenom
approach
character
dna
rna
present
sampl
enabl
analysi
entir
microbiom
well
human
host
genom
transcriptom
patient
sampl
metagenom
approach
appli
decad
charac
teriz
variou
nich
rang
marin
environ
ment
toxic
soil
arthropod
diseas
vector
human
microbiom
tool
also
use
identifi
infect
ancient
remain
discov
novel
viral
pathogen
character
human
virom
healthi
diseas
state
forens
applic
capac
detect
potenti
pathogensbacteria
virus
fungi
parasit
sampl
simultan
interrog
host
respons
great
potenti
util
diagnosi
infecti
diseas
metagenom
clinic
applic
deriv
root
use
microarray
earli
earli
success
use
technolog
includ
discov
eri
sar
coronaviru
gene
profil
muta
tion
cancer
depth
microbiom
analysi
differ
site
human
bodi
howev
advent
next
gener
sequenc
ng
techno
logi
jump
start
metagenom
field
first
time
million
billion
read
could
gener
singl
run
permit
analysi
entir
genet
content
clinic
environment
sampl
prolifer
avail
sequenc
instru
ment
exponenti
decreas
sequenc
cost
ensu
decad
drove
rapid
adopt
ng
technolog
date
sever
studi
provid
glimps
promis
ng
clinic
public
health
set
exampl
ng
use
clinic
diagnosi
neuroleptospirosi
old
critic
ill
boy
meningoenceph
case
first
demonstr
util
metagenom
ng
mng
provid
clinic
action
inform
success
ful
diagnosi
prompt
appropri
target
antibiot
treatment
eventu
recoveri
patient
exampl
public
health
microbiolog
includ
use
ng
combin
transmiss
network
analysi
investig
outbreak
escherichia
coli
strain
ref
surveil
antimicrobi
resist
food
suppli
bacteri
whole
genom
sequenc
increasingli
big
data
provid
mng
leverag
clinic
purpos
includ
charac
teriz
antibiot
resist
directli
clinic
sampl
analysi
human
host
respons
tran
scriptom
data
predict
caus
infect
evalu
ate
diseas
risk
thu
mng
key
driver
precis
diagnosi
infecti
diseas
advanc
precis
medicin
effort
person
patient
care
field
despit
potenti
recent
success
metagenom
clinic
diagnost
applic
lag
behind
research
advanc
owe
number
factor
complex
interplay
microbi
host
factor
influenc
human
health
exemplifi
role
microbiom
modul
host
immun
respons
often
unclear
whether
detect
microorgan
contamin
colon
bona
fide
pathogen
addit
univers
refer
standard
entireti
organ
colon
individu
site
human
bodi
commonli
refer
chip
platform
consist
spot
dna
fragment
antibodi
protein
print
onto
surfac
enabl
massiv
multiplex
hundr
thousand
target
dna
sequenc
read
infer
sequenc
base
pair
correspond
part
singl
dna
fragment
mng
shotgun
sequenc
approach
genom
content
dna
andor
rna
clinic
environment
sampl
sequenc
proven
approach
demonstr
test
valida
tion
reproduc
qualiti
assur
clinic
metagenom
assay
lack
consider
cost
reimburs
turnaround
time
regulatori
considera
tion
perhap
importantli
clinic
util
also
remain
major
hurdl
routin
implement
clinic
mng
patient
care
set
review
variou
applic
mng
current
exploit
clinic
public
health
set
discuss
challeng
involv
adopt
mng
clinic
laboratori
includ
valid
regulatori
consider
extend
beyond
initi
develop
research
laboratori
propos
step
overcom
challeng
final
envisag
futur
direct
field
clinic
metagenom
anticip
achiev
next
year
date
applic
clinic
metagenom
includ
infecti
diseas
diagnost
varieti
syndrom
sampl
type
microbiom
analys
diseas
healthi
state
character
human
host
respons
infect
transcriptom
identif
tumour
associ
virus
genom
integr
site
fig
tabl
asid
infecti
diseas
diagnost
adopt
mng
clinic
laboratori
slow
applica
tion
yet
incorpor
routin
clinic
practic
nonetheless
breadth
potenti
clini
cal
util
applic
like
transform
field
diagnost
microbiolog
near
futur
tradit
clinic
paradigm
diagnosi
infec
tiou
diseas
patient
appli
centuri
involv
physician
formul
differenti
diagnosi
order
seri
test
gener
one
bug
one
test
attempt
identifi
caus
agent
spectrum
convent
test
pathogen
clinic
sampl
rang
identif
microorgan
grow
cultur
exampl
biochem
phenotyp
test
matrix
assist
laser
desorptionion
maldi
time
offlight
mass
spectrometri
detect
organ
specif
bio
marker
antigen
test
latex
agglutin
antibodi
test
enzym
link
immunosorb
assay
elisa
nucleic
acid
test
pcr
sin
gle
agent
multiplex
pcr
test
use
syndrom
panel
panel
gener
includ
common
pathogen
associ
defin
clinic
syndrom
mening
enceph
acut
respiratori
infect
sepsi
diarrhoeal
diseas
molecular
diagnost
assay
provid
fairli
cost
effect
rapid
gener
hour
turnaround
time
mean
diagnos
common
infect
howev
nearli
convent
microbiolog
test
current
use
detect
one
limit
panel
patho
gen
time
requir
microorgan
suc
cess
cultur
clinic
sampl
contrast
ng
assay
current
use
compar
convent
test
respect
speed
sequenc
ing
run
alon
standard
illumina
instrument
take
hour
mng
enabl
broad
rang
pathogen
virus
bacteria
fungi
andor
parasit
identifi
cultur
directli
clinic
sampl
basi
uniqu
identifi
dna
andor
rna
sequenc
anoth
key
advantag
ng
approach
sequenc
data
potenti
leverag
addit
analys
beyond
mere
identif
caus
pathogen
microbiom
charact
izat
parallel
analys
human
host
respons
transcriptom
profil
rna
sequenc
rna
seq
thu
clinic
util
ng
diagno
si
may
difficult
todiagnos
case
immunocompromis
patient
spectrum
potenti
pathogen
greater
eventu
mng
may
becom
cost
competit
multiplex
assay
use
upfront
rule
assay
exclud
infec
tiou
aetiolog
cours
detect
nucleic
acid
either
multiplex
pcr
panel
ng
prove
identifi
microorgan
caus
ill
find
interpret
clinic
context
particular
discoveri
atyp
novel
infecti
agent
clinic
sampl
fig
clinic
applic
metagenom
sequenc
applic
infecti
diseas
diagnost
includ
direct
identif
microorgan
primari
clinic
sampl
part
aa
antimicrobi
resist
predict
character
resist
gene
part
ab
detect
specieslevel
strainlevel
virul
determin
secret
specif
endotoxin
exotoxin
part
ac
antivir
resist
predict
part
ad
shown
recoveri
complet
viral
genom
patient
sampl
metagenom
nextgener
sequenc
mng
part
ad
graph
facilit
sequenc
analysi
predict
suscept
resist
antiretrovir
drug
part
ad
bar
plot
suscept
profil
analys
strain
black
bar
predict
resist
nonnucleosid
revers
transcriptas
inhibitor
nnrti
class
drug
denot
asterisk
oppos
nucleosid
revers
transcriptas
inhibitor
nrti
proteas
inhibitor
pi
b
microbiom
analys
inform
diseas
prognosi
acut
chronic
diseas
state
underli
develop
probiot
therapi
colour
bar
repres
individu
microbiota
speci
reduct
speci
divers
seen
dysbiosi
unhealthi
state
present
patient
clostridium
difficileassoci
diseas
stool
healthi
individu
harvest
treat
patient
c
difficil
infect
faecal
stool
transplant
oral
administ
encapsul
faecal
pill
altern
synthet
stool
gener
microbiota
speci
observ
healthi
individu
use
probiot
treat
patient
addit
c
difficil
infect
chronic
diseas
obes
inflammatori
bowel
diseas
diabet
mellitu
potenti
target
probiot
therapi
c
rnasequencingbas
transcriptom
improv
diagnosi
infecti
noninfecti
condit
basi
human
host
respons
host
transcriptom
profil
ng
enabl
construct
classifi
metric
discrimin
patient
infect
red
bar
uninfect
patient
blue
bar
high
accuraci
part
ca
metric
score
dot
line
indic
infect
wherea
score
dot
line
indic
absenc
infect
overal
accuraci
classifi
metric
shown
cluster
heat
map
analysi
identifi
individu
differenti
express
host
gene
associ
infect
gene
af
versu
associ
infect
gene
gl
part
cb
sequenc
viral
tumour
liquid
biopsi
analys
oncolog
use
simultan
pathogen
detect
character
host
genet
mutat
mng
use
detect
merkel
cell
polyomaviru
viru
associ
develop
merkel
cell
carcinoma
simultan
sequenc
host
dna
identifi
mutat
aris
integr
viral
genom
contain
fulllength
larg
antigen
lt
follow
subsequ
truncat
lt
antigen
part
da
truncat
lt
antigen
viral
genom
integr
part
db
two
mutat
lead
cellular
transform
drive
tumour
prolifer
although
promis
mani
sequencingbas
applic
yet
incorpor
routin
clinic
practic
part
c
adapt
ref
cc
byncnd
http
part
adapt
ref
cc
http
integr
epidemiolog
laboratori
genom
data
track
pattern
transmiss
infer
origin
date
infect
outbreak
approach
medic
care
diseas
treatment
prevent
take
account
genet
inform
obtain
genom
molecular
profil
clinic
sampl
laboratori
test
develop
wellcharacter
standard
valid
refer
materi
databas
enabl
measur
perform
characterist
assay
includ
sensit
specif
accuraci
follow
confirmatori
investig
orthogon
test
tissu
biopsi
sampl
demon
stration
seroconvers
via
use
cell
cultur
anim
model
appropri
ascertain
true
pathogen
potenti
ng
clinic
sampl
perform
either
research
clinic
laboratori
involv
number
step
includ
nucleic
acid
extract
enrich
dna
andor
rna
librari
prepar
pcr
ampli
ficat
need
sequenc
bioinformat
ic
analysi
fig
bodi
fluid
tissu
yield
suffici
nucleic
acid
amen
ng
analysi
either
target
enrich
indi
vidual
gene
genom
region
untarget
case
metagenom
shotgun
approach
fig
detail
specif
step
vari
laboratori
describ
extens
elsewher
target
approach
benefit
increas
number
proport
pathogen
read
sequenc
data
step
increas
detect
sensit
microorgan
target
although
limit
breadth
poten
tial
pathogen
identifi
exampl
target
approach
use
highli
conserv
prim
er
univers
pcr
amplif
detect
microorgan
correspond
specif
type
clinic
sampl
ribosom
rna
rrna
gene
amplif
bacteria
rrna
intern
transcrib
spacer
gene
amplif
clinic
laboratori
test
detect
specif
antibodi
correspond
antigen
adsorb
spheric
polystyren
latex
particl
undergo
agglutin
presenc
antibodi
develop
detect
antibodi
blood
direct
infecti
agent
infecti
diseas
detect
serolog
test
antibodi
wwwnaturecomnrg
june
volum
fungi
fig
previous
approach
follow
sanger
sequenc
result
pcr
amplicon
identifi
pathogen
make
diagnosi
step
commonli
accomplish
use
ng
univers
pcr
detect
bacteria
fungi
adopt
mani
hospit
laboratori
increas
number
proport
infecti
diagnos
although
techniqu
limit
breadth
detect
bacteria
fungi
even
limit
rang
target
mycobacteria
depend
primer
set
use
concern
regard
sensit
anoth
exampl
target
ng
approach
design
primer
tile
across
genom
facilit
pcr
amplif
amplicon
ng
recoveri
viral
genom
directli
clinic
sampl
method
use
track
evolut
spread
zika
viru
zikv
america
ebola
viru
west
africa
demonstr
real
time
monitor
impact
public
health
intervent
anoth
target
approach
captur
probe
enrich
ment
wherebi
metagenom
librari
subject
hybrid
use
captur
bait
probe
probe
gener
bp
length
num
ber
probe
vari
less
million
although
enrich
method
shown
increas
sensit
metagenom
detec
tion
research
set
especi
virus
yet
use
routin
clinic
diagnosi
promis
appli
cation
approach
may
enrich
clinic
sampl
character
antibiot
resist
consider
problem
hospit
primari
focu
us
nation
action
plan
combat
antibiot
resist
bacteria
howev
drawback
captur
probe
enrich
compar
untarget
approach
infecti
diseas
diagnosi
includ
bia
toward
tar
gete
microorgan
ad
step
increas
cost
long
hybrid
time
hour
result
addit
process
need
maxim
effici
untarget
shotgun
mng
analys
forego
use
specif
primer
probe
instead
entireti
dna
andor
rna
revers
transcript
cdna
sequenc
pure
cultur
bacteria
fungi
mng
read
assembl
partial
complet
genom
genom
sequenc
use
subtyp
andor
monitor
hospit
outbreak
sup
port
infect
control
andor
public
health
surveil
lanc
effort
exampl
semin
studi
describ
use
whole
genom
sequenc
multidrug
resist
carbapenemas
produc
klebsiella
pneumonia
track
origin
evolut
hospit
outbreak
studi
demonstr
first
time
high
resolut
map
like
transmiss
event
hospit
unexpect
basi
initi
epidemiolog
data
also
identifi
puta
tive
resist
mutat
emerg
resist
strain
integr
genom
epidemiolog
data
yield
action
insight
would
use
curb
transmiss
untarget
mng
clinic
sampl
perhap
promis
approach
comprehens
diagnosi
infect
principl
nearli
patho
gen
includ
virus
bacteria
fungi
parasit
identifi
singl
assay
mng
needl
ina
haystack
endeavour
small
proport
typic
read
non
human
subset
may
correspond
potenti
pathogen
limit
mng
sensit
approach
critic
depend
level
back
ground
tissu
exampl
increas
human
host
background
rel
cell
free
bodi
fluid
result
ing
reduc
number
proport
microbi
read
henc
decreas
mng
sensit
moreov
defin
specif
microbi
profil
diagnost
predict
diseas
develop
difficult
especi
nonsteril
site
harbour
complex
microbiom
respiratori
secret
stool
nevertheless
sever
group
success
valid
mng
clinic
laboratori
improv
amend
clia
certifi
clinic
laboratori
diagnosi
infect
includ
mening
enceph
sepsi
pneumonia
assay
avail
clinic
refer
test
patient
mani
research
use
mng
instead
target
sequenc
rrna
gene
depth
charac
teriz
microbiom
grow
public
awar
microbiom
like
involv
acut
chronic
diseas
state
howev
microbiom
base
test
clinic
valid
diagnosi
treatment
diseas
part
owe
incomplet
understand
complex
microbiom
role
diseas
pathogenesi
one
futur
clinic
applic
microbiom
analysi
may
manag
treatment
clostridium
difficil
associ
diseas
c
difficil
opportunist
bacterium
infect
gut
result
ing
product
toxin
caus
diarrhoea
dehydr
sepsi
death
c
difficil
infect
occur
set
microbiom
alter
factor
exposur
broad
spectrum
anti
biotic
recent
gastrointestin
surgeri
import
microbiom
c
difficil
infect
underscor
effect
faecal
stool
transplan
tation
treat
potenti
cure
diseas
use
mng
character
microbiom
multipl
studi
facilit
develop
bac
terial
probiot
mixtur
administ
pill
prophylaxi
treatment
c
difficil
associ
diseas
fig
anoth
potenti
applic
microbiom
analysi
bacteri
divers
provid
clue
whether
patient
ill
infecti
non
infecti
exampl
studi
mng
identif
respiratori
pathogen
patient
pneumonia
found
individu
cultur
proven
infect
significantli
less
divers
re
piratori
microbiom
alter
microbiom
known
dysbiosi
also
shown
relat
librari
dna
sequenc
collect
dna
fragment
known
adapt
sequenc
one
end
deriv
singl
clinic
environment
sampl
classic
method
dna
sequenc
base
select
incorpor
chaintermin
dideoxynucleotid
develop
frederick
sanger
colleagu
larg
supplant
nextgener
sequenc
microbiolog
refer
identif
specif
genet
variant
strain
microorgan
exampl
viru
bacterium
fungu
usual
sequenc
part
genom
amplif
target
region
target
mng
target
mng
wwwnaturecomnrg
june
volum
obes
diabet
mellitu
inflammatori
bowel
diseas
manipul
microbiom
may
pathway
treat
patholog
condit
clinic
mng
typic
focus
microbi
read
howev
complementari
role
analysi
gene
express
studi
human
host
respons
infect
fig
mng
rna
librari
use
detect
pathogen
rna
virus
clinic
sampl
incident
produc
host
gene
express
data
transcriptom
rna
seq
analys
although
rna
seq
analys
commonli
perform
whole
blood
peripher
blood
mononuclear
cell
pbmc
sampl
bodi
fluid
tissu
type
potenti
amen
analys
classif
gene
express
profil
use
rna
seq
use
character
sever
infect
includ
staphylococc
bactera
mia
lyme
diseas
candidiasi
tuberculosi
di
crimin
latent
activ
diseas
risk
influenza
machin
learningbas
analys
rna
seq
data
use
cancer
classifi
cation
translat
approach
may
promis
infecti
diseas
panel
contain
limit
number
host
biomark
develop
diagnost
assay
influenza
tuberculosi
bacteri
sepsi
although
rna
seqbas
assay
clinic
valid
date
use
patient
potenti
clin
ical
impact
rna
seq
analys
high
interrog
rna
read
microorgan
correspond
activ
microbi
gene
express
might
enabl
di
crimin
infect
versu
colon
live
viabl
versu
dead
organ
moreov
rna
seq
analys
human
host
use
identifi
novel
underappreci
hostmicrobi
interact
directli
clinic
sampl
previous
shown
patient
lyme
diseas
dengu
malaria
rna
seq
may
particularli
use
clinic
case
caus
pathogen
transient
present
earli
lyme
diseas
arbovir
infect
includ
west
nile
viru
zikv
analog
serolog
test
indirect
diagnosi
infect
may
possibl
basi
pathogen
specif
human
host
respons
analysi
pathogen
specif
host
respons
may
also
use
discrimin
bona
fide
caus
pathogen
pathogen
complex
clinic
metagenom
sampl
polymicrobi
abscess
respiratori
fluid
yet
anoth
promis
applica
tion
rna
seq
discrimin
infecti
versu
non
infecti
caus
acut
ill
ill
judg
like
non
infecti
exampl
autoimmun
diseas
basi
host
respons
exampl
clinician
may
will
discon
tinu
antibiot
treat
patient
aggress
steroid
immunosuppress
medic
larg
scale
sequenc
data
continu
gener
ate
perhap
driven
routin
clinic
mng
test
secondari
mine
human
read
might
improv
accuraci
clinic
diagnos
incorpor
microbi
host
gene
express
data
oncolog
whole
genom
direct
ng
approach
identifi
mutat
gene
use
simultan
uncov
virus
associ
cancer
herp
virus
papillomavirus
polyomavirus
andor
gather
data
virushost
interact
exam
ple
mng
critic
discoveri
merkel
cell
polyomaviru
fig
believ
caus
merkel
cell
carcinoma
rare
skin
cancer
seen
commonli
elderli
patient
date
us
food
drug
administr
fda
approv
clinic
use
two
ng
panel
test
action
genom
aberr
tumour
sampl
detect
read
cor
respond
integr
exogen
virus
sampl
would
possibl
addit
specif
viral
probe
panel
accomplish
inci
dental
sequenc
whole
tumour
genom
exom
addit
knowledg
integr
activ
viral
infect
cancer
involv
signal
ling
pathway
may
inform
prevent
therapeut
intervent
target
antivir
andor
chemothera
peutic
drug
evidenc
decreas
risk
hepat
c
viru
associ
hepatocellular
carcinoma
treatment
direct
act
antivir
agent
futur
mng
cell
free
dna
liquid
biopsi
sampl
exampl
plasma
might
leverag
simultan
identif
earli
cancer
diagnosi
infect
immunocompromis
patient
box
clinic
implement
metagenom
ng
implement
mng
clinic
laboratori
complex
endeavour
requir
custom
research
protocol
use
qualiti
manag
approach
consist
regulatori
standard
librari
prepara
tion
reagent
sequenc
instrument
bioin
format
tool
constantli
chang
research
environ
howev
clinic
laboratori
assay
need
implement
follow
standard
lock
protocol
chang
made
compon
detect
molecular
biomark
minim
invas
sampl
clinic
bodi
fluid
dna
sequenc
blood
purpos
diagnos
diseas
fig
target
versu
untarget
shotgun
metagenom
nextgener
sequenc
approach
varieti
patient
sampl
well
cultur
microbi
coloni
analys
use
target
untarget
metagenom
nextgener
sequenc
mng
method
pathogen
identif
microbiom
analys
andor
host
transcriptom
profil
univers
pcr
left
target
mng
approach
use
primer
design
conserv
region
ribosom
rna
rrna
gene
univers
conserv
among
bacteria
rrna
fungi
parasit
rrna
rrna
intern
transcrib
spacer
set
primer
design
target
defin
set
pathogen
andor
gene
use
multiplex
revers
transcript
pcr
pcr
multiplex
amplicon
pcr
ng
librari
prepar
sequenc
result
amplicon
enabl
pathogen
identif
genu
speci
level
metagenom
sequenc
right
entail
unbias
shotgun
sequenc
microbi
host
nucleic
acid
present
clinic
sampl
separ
dna
rna
librari
construct
dna
librari
use
identif
bacteria
fungi
dna
virus
parasit
wherea
rna
librari
use
identif
rna
virus
rna
sequencingbas
human
host
transcriptom
profil
heat
map
bottom
right
primer
probe
use
unbias
mng
vast
major
read
correspond
human
host
thu
detect
pathogen
metagenom
librari
needleinahaystack
endeavour
option
captur
probe
enrich
step
use
magnet
bead
enabl
target
mng
pathogen
andor
gene
metagenom
librari
method
compat
sequenc
tradit
benchtop
instrument
illumina
hiseq
portabl
nanopor
sequenc
oxford
nanopor
technolog
minion
assay
need
valid
shown
accept
perform
test
patient
period
updat
repeat
valid
studi
perform
deem
necessari
incorpor
interim
technolog
advanc
ng
reagent
protocol
instrument
metagenom
method
pathogen
detect
pre
ent
particularli
challeng
scenario
clinic
vali
dation
fig
practic
test
essenti
unlimit
number
differ
organ
assay
consid
valid
although
fda
pro
vide
gener
guidelin
clinic
valid
ng
infecti
diseas
test
definit
reco
mmendat
clinic
implement
mng
test
mention
specif
requir
howev
best
practic
approach
taken
includ
failur
mode
analysi
evalu
per
formanc
characterist
use
repres
organ
ism
ongo
assay
monitor
independ
confirm
unexpect
result
key
limit
mng
decreas
sensit
high
background
either
predominantli
human
host
exampl
tissu
biopsi
microbiom
exampl
stool
background
clini
calli
relev
pathogen
load
infect
shigella
flexneri
stool
patient
diarrhoea
zikv
plasma
patient
vector
born
febril
ill
low
copi
per
ml
host
deplet
method
rna
librari
develop
shown
effect
includ
dnase
treatment
extract
remov
residu
human
background
dna
use
rna
probe
follow
rnase
h
treatment
antibodi
human
mitochondri
rrna
abund
host
rna
type
clinic
sampl
andor
approach
deplet
abund
sequenc
hybrid
unfortun
compar
effect
parallel
method
dna
librari
limit
enrich
ment
time
rang
achiev
use
antibodi
methyl
human
host
dna
enrich
microbi
read
owe
lack
methyl
dna
pathogen
genom
differenti
lysi
human
cell
follow
degrada
tion
background
dna
dnase
thu
retain
ing
enrich
nucleic
acid
organ
cell
wall
includ
bacteria
fungi
shown
provid
substanti
microbi
enrich
time
howev
perform
differenti
lysi
method
limit
number
factor
limit
includ
potenti
decreas
sensit
microorgan
without
cell
wall
mycoplasma
spp
parasit
possibl
paradoxi
cal
increas
exogen
background
contamin
use
addit
reagent
inabl
detect
free
nucleic
acid
dead
organ
lyse
vivo
human
host
immun
cell
antibiot
treatment
import
retain
abil
cell
free
dna
detect
cultur
neg
sampl
dead
organ
also
incorpor
propidium
monoazid
treatment
step
select
dna
live
organ
may
clinic
use
enrich
method
mng
gener
differenti
lysi
propidium
monoazid
approach
would
also
cumbersom
implement
highli
reproduc
fashion
need
clinic
laboratori
valid
extent
human
host
background
limi
tation
may
overcom
brute
forc
made
possi
ble
increas
capac
avail
sequenc
instanc
astroviru
detect
child
enceph
ultradeep
sequenc
brain
tissu
yield
read
million
sequenc
yet
anoth
approach
improv
sensitiv
iti
leverag
hybrid
method
enrich
metagenom
sequenc
spike
primer
combin
target
untarget
sequenc
method
use
variabl
size
panel
short
primer
ad
spike
reaction
mixtur
enrich
specif
target
organ
retain
breadth
metagenom
sequenc
target
organ
spike
revers
transcript
step
panel
zikv
specif
primer
found
increas
number
zikv
read
ten
fold
without
appreci
decreas
broad
metagenom
sensit
pathogen
enabl
whole
genom
viral
sequenc
character
zikv
spread
brazil
central
america
mexico
complex
mng
analysi
requir
highli
train
personnel
extrem
care
sampl
handl
avoid
error
cross
contamin
even
miniscul
amount
exogen
dna
rna
introduc
sampl
collect
aliquot
nucleic
acid
extract
librari
prepar
pool
yield
detect
signal
contamin
read
addit
labora
tori
surfac
consum
reagent
dna
free
databas
background
microorgan
com
monli
detect
mng
data
aris
mal
flora
laboratori
contamin
typic
need
maintain
accur
mng
analys
microorgan
list
either
report
requir
higher
threshold
report
clinic
signific
organ
metagenom
sequenc
clinic
diagnost
purpos
typic
use
shotgun
approach
sequenc
dna
andor
rna
clinic
sampl
clinic
sampl
vari
significantli
cellular
rang
cellfre
fluid
plasma
bronchoalveolar
lavag
fluid
centrifug
cerebrospin
fluid
tissu
nextgener
sequenc
ng
field
great
interest
use
liquid
biopsi
cellfre
dna
cfdna
extract
bodi
fluid
plasma
identifi
chromosom
genet
mutat
thu
diagnos
malign
presymptomat
phase
similarli
cfdna
analysi
use
noninvas
prenat
test
applic
identif
trisomi
ref
one
studi
describ
potenti
util
cfdna
analysi
diagnos
invas
fungal
infect
case
biopsi
possibl
anoth
advantag
cfdna
analysi
higher
sensit
metagenom
sequenc
owe
less
cellular
background
human
host
howev
limit
cfdna
analysi
may
includ
decreas
sensit
detect
predominantli
intracellular
pathogen
human
cell
lymphotrop
viru
rickettsia
spp
pneumocysti
jirovecii
loss
abil
interrog
cellular
human
host
respons
rna
sequenc
clinic
laboratori
oper
character
defin
workflow
schedul
staf
level
less
amen
demand
test
research
laboratori
sampl
typic
handl
batch
frequenc
batch
analysi
major
deter
minant
overal
turnaround
time
unless
fulli
auto
mate
sampl
handl
system
readili
avail
wet
lab
manipul
mng
requir
consider
hand
time
perform
well
clinic
staff
highli
train
molecular
biolog
procedur
ergonom
concern
repetit
task
pipet
well
potenti
inadvert
sampl
mix
omiss
critic
step
work
flow
maintain
high
qualiti
complex
mng
fig
challeng
routin
deploy
metagenom
sequenc
clinic
set
step
process
multipl
factor
bullet
point
must
taken
account
implement
clinic
metagenom
pipelin
diagnosi
infect
maxim
accuraci
clinic
relev
particular
often
use
interpret
discuss
result
metagenom
nextgenerationsequenc
mng
test
clinic
context
part
clinic
microbi
sequenc
board
akin
tumour
board
oncolog
emr
electron
medic
record
procedur
stress
staff
slight
deviat
sampl
handl
lead
major
chang
result
gener
separ
assay
workflow
multipl
discret
step
perform
rotat
shift
help
avoid
laboratori
error
well
character
refer
standard
control
need
ensur
mng
assay
qualiti
stabil
time
avail
metagenom
refer
materi
highli
custom
specif
applic
exam
ple
zymobiom
microbi
commun
standard
microbiom
analys
bacteri
fungal
meta
genom
andor
focus
limit
spec
trum
organ
exampl
nation
institut
standard
technolog
nist
refer
materi
mix
microbi
dna
detect
contain
bacteria
thu
materi
may
applic
untarget
mng
analys
custom
mixtur
consist
pool
micro
organ
mock
microbi
commun
nucleic
acid
develop
extern
control
establish
limit
detect
mng
test
intern
spikein
control
standard
avail
ng
applic
transcriptom
analysi
rna
seq
extern
rna
control
consortium
ercc
rna
standard
compos
synthet
rna
oligonu
cleotid
span
rang
nucleotid
length
concentr
complet
set
portion
ercc
rna
standard
dna
equival
use
spike
intern
control
control
assay
inhibit
quantifi
titr
detect
pathogen
standard
curv
analysi
nonetheless
lack
univers
accept
refer
standard
mng
make
difficult
compar
assay
perform
differ
laboratori
critic
need
standard
refer
organ
genom
materi
facilit
comparison
defin
optim
analysi
method
user
friendli
bioinformat
softwar
analysi
mng
data
current
avail
thu
custom
bioinformat
pipelin
analysi
clinic
mng
data
still
requir
highli
train
program
staff
develop
valid
maintain
pipelin
clinic
use
laboratori
either
host
comput
serv
er
local
move
bioinformat
analysi
data
storag
cloud
platform
either
case
hardwar
softwar
setup
complex
adequ
measur
must
place
protect
confidenti
patient
sequenc
data
inform
especi
cloud
environ
storag
requir
sequenc
data
quickli
becom
quit
larg
clinic
laboratori
must
decid
quantiti
locat
durat
data
storag
bioinformat
pipelin
mng
analysi
use
number
differ
algorithm
usual
develop
research
set
constantli
updat
soft
ware
develop
wet
lab
procedur
usual
nece
sari
make
custom
modif
pipelin
softwar
lock
softwar
ref
erenc
databas
purpos
clinic
valid
typi
cal
bioinformat
pipelin
consist
seri
analysi
step
raw
input
fastq
file
includ
qualiti
low
complex
filter
adaptor
trim
human
host
subtract
microorgan
identif
align
refer
databas
option
sequenc
assembl
taxonom
classif
individu
read
andor
contigu
sequenc
contig
level
famili
genu
speci
fig
step
pipelin
must
care
assess
accuraci
complet
data
process
consider
propag
error
sensit
analys
perform
inclus
silico
data
data
gener
clinic
sampl
custom
data
set
prepar
mimic
input
sequenc
data
expand
rang
microorgan
detect
silico
analysi
use
standard
refer
mate
rial
ng
data
set
also
help
compar
evalu
differ
bioinformat
pipelin
addit
public
databas
microbi
refer
genom
continu
updat
laborato
rie
need
keep
track
exact
version
use
addi
tion
deal
potenti
misannot
databas
error
larger
complet
databas
contain
publicli
deposit
sequenc
nation
center
biotechnolog
inform
ncbi
nucleotid
databas
comprehens
also
contain
error
curat
limit
data
base
fda
argo
fda
refer
viral
databas
rvdb
combin
approach
incorpor
annot
sequenc
multipl
data
base
may
enabl
greater
confid
sensit
specif
microorgan
identif
perform
valid
verif
bioinfor
matic
analysi
constitut
time
consum
endeavour
includ
analysi
control
patient
data
set
comparison
orthogon
clinic
test
deter
mine
accuraci
final
result
establish
threshold
enabl
separ
true
posit
match
background
threshold
incor
porat
metric
number
sequenc
read
align
detect
microorgan
normal
read
per
million
extern
notempl
control
sampl
intern
spike
materi
number
nonoverlap
genom
region
cover
read
abund
clin
ical
sampl
rel
neg
control
sampl
avoid
report
contamin
organ
receiveroper
curv
roc
analysi
use
tool
determin
opti
mal
threshold
valu
train
set
clinic
sampl
known
result
verif
pre
establish
threshold
use
independ
valid
set
wet
lab
workflow
analysi
softwar
ref
erenc
databas
ideal
lock
valid
clinic
use
mani
laboratori
maintain
product
todat
develop
version
clinic
refer
databas
exampl
ncbi
nucleotid
databas
updat
everi
week
product
databas
updat
regular
prespec
ifi
interv
standard
data
set
use
verifi
databas
updat
ensur
assay
result
accur
reproduc
error
introduc
newli
deposit
sequenc
clinic
metadata
laboratori
test
develop
refer
use
nucleic
acid
fragment
posit
control
microorgan
ad
neg
sampl
matrix
exampl
plasma
blood
donor
clinic
sampl
serv
intern
control
assay
pcr
sequenc
reaction
neg
control
sampl
dna
cdna
left
thu
monitor
contamin
could
produc
falseposit
result
wwwnaturecomnrg
june
volum
although
substanti
cost
reduct
gener
sequenc
data
overal
per
sampl
reagent
cost
sequenc
remain
fairli
high
lab
oratori
lack
robot
equip
establish
autom
protocol
multiplex
larg
number
patient
sampl
singl
run
thu
major
librari
prepar
method
mng
perform
manual
henc
incur
consider
staff
time
addit
resourc
need
run
maintain
fig
typic
metagenom
nextgener
sequenc
bio
informat
pipelin
nextgener
sequenc
ng
data
set
gener
fastq
sequenc
align
map
sam
format
analys
comput
server
portabl
laptop
desktop
comput
cloud
initi
preprocess
step
consist
lowqual
filter
lowcomplex
filter
adaptor
trim
comput
host
subtract
perform
map
read
host
exampl
human
genom
set
asid
host
read
subsequ
transcriptom
rna
genom
dna
analysi
remain
unmap
read
directli
align
larg
refer
databas
nation
center
biotechnolog
inform
ncbi
genbank
databas
microbi
refer
sequenc
genom
collect
first
assembl
de
novo
longer
contigu
sequenc
contig
follow
align
refer
databas
taxonom
classif
individu
read
contig
assign
specif
taxa
exampl
speci
genu
famili
data
analys
visual
number
differ
format
includ
coverag
map
pairwis
ident
plot
determin
much
microbi
genom
recov
similar
refer
genom
databas
krona
plot
visual
taxonom
divers
metagenom
librari
phylogenet
analysi
compar
assembl
gene
gene
region
genom
refer
sequenc
heat
map
show
microorgan
detect
clinic
sampl
otu
oper
taxonom
unit
bioinformat
analysi
pipelin
also
consider
step
taken
ensur
regulatori
oversight
add
notabl
cost
well
lead
overal
cost
sever
hundr
thousand
dollar
per
sam
ple
analys
higher
mani
clinic
test
technic
improv
hardwar
need
mng
sampl
process
increas
throughput
reduc
cost
ng
procedur
becom
standard
drive
toward
increas
autom
use
liquid
handl
biorobot
typic
two
biorobot
need
clinic
mng
pre
amplif
post
amplif
step
avoid
pcr
amplicon
cross
contamin
increas
multiplex
also
possibl
greatli
enhanc
output
latest
gener
sequenc
er
illumina
novaseq
instrument
howev
potenti
limit
run
larger
number
sampl
per
run
longer
overal
turnaround
time
clinic
use
owe
requir
batch
pro
cess
well
sampl
workflow
comput
analysi
consider
addit
high
throughput
process
clinic
sampl
ng
may
possibl
refer
laboratori
develop
microfluid
devic
ng
sampl
librari
prepar
voltrax
could
eventu
enabl
clinician
use
mng
wide
hospit
laboratori
pointofcar
set
clinic
laboratori
highli
regul
gener
laboratori
test
requir
appli
mole
cular
diagnost
assay
report
patient
care
qualiti
control
paramount
method
must
develop
ensur
analyt
accuraci
throughout
assay
workflow
import
qualiti
control
step
includ
initi
sampl
qualiti
check
librari
param
eter
concentr
size
distribut
sequenc
data
gener
cluster
densiti
qscore
recoveri
intern
control
perform
extern
control
valid
data
gener
assay
develop
implement
record
made
availa
ble
laboratori
inspector
laboratori
develop
test
submit
regulatori
agenc
fda
usa
european
medicin
agenc
ema
europ
approv
ongo
monitor
particularli
import
mng
assay
verifi
accept
perform
time
investig
atyp
find
monitor
accomplish
use
sampl
intern
control
intra
run
control
sampl
swipe
test
contamin
perio
dic
profici
test
unexpect
unusu
result
investig
review
patient
clinic
chart
confirmatori
laboratori
test
use
orthogon
method
identif
microorgan
identifi
laboratori
independ
confirm
usual
clinic
ref
erenc
public
health
laboratori
test
atyp
novel
organ
assess
clinic
signific
find
report
discuss
health
care
provid
consider
potenti
pathogen
test
treatment
option
clinic
microbi
sequenc
board
model
tumour
board
oncolog
conven
via
real
time
teleconferenc
discuss
mng
result
treatment
provid
clinic
con
text
fig
detect
microorgan
public
health
implic
sin
nombr
hantaviru
ebola
viru
report
appropri
relev
public
health
agenc
technolog
advanc
librari
prepar
method
sequenc
gener
comput
bio
informat
enabl
quicker
comprehen
sive
metagenom
analys
lower
cost
sequenc
technolog
applic
continu
evolv
real
time
sequenc
particular
may
game
chang
technolog
point
ofcar
applic
clinic
medicin
public
health
laboratori
begun
appli
tool
diagnos
atyp
infec
tion
track
pathogen
outbreak
demonstr
recent
deploy
real
time
nanopor
sequenc
remot
epidemiolog
surveil
ebola
zikv
even
use
aboard
intern
space
station
box
nonetheless
formid
challeng
remain
implement
mng
routin
patient
care
par
ticular
sensit
pathogen
detect
decreas
clinic
sampl
high
nucleic
acid
background
exceedingli
low
pathogen
titr
concern
box
nanopor
sequenc
nanopor
sequenc
emerg
nextgener
sequenc
ng
technolog
enabl
realtim
analysi
sequenc
data
particularli
applic
metagenom
ng
mng
approach
time
essenc
treat
patient
acut
infecti
diseas
date
commerci
avail
instrument
nanopor
sequenc
oxford
nanopor
technolog
includ
minion
flow
cell
gridion
flow
cell
capac
promethion
flow
cell
capac
publish
research
studi
mngsbase
detect
ebola
chikungunya
viru
infect
nanopor
sequenc
possibl
minut
sequenc
time
hour
sampletoansw
turnaround
time
overal
research
studi
also
demonstr
clinic
potenti
nanopor
sequenc
target
univers
ribosom
rna
rrna
bacteri
detect
microbiom
analys
wholegenom
sequenc
bacteria
outbreak
virus
rna
sequenc
rnaseq
use
standard
control
diagnosi
prosthet
joint
lower
respiratori
infect
untarget
approach
mng
wholetranscriptom
rnaseq
howev
may
limit
lower
throughput
nanopor
sequenc
rel
shortread
sequenc
illumina
instrument
current
ngsbase
clinic
test
pathogen
valid
nanopor
sequenc
platform
clinic
adopt
devic
limit
rapid
pace
improv
platform
hinder
clinic
valid
effort
requir
standard
instrument
lockeddown
protocol
ongo
issu
regard
sequenc
qualiti
yield
nonetheless
enorm
potenti
nanopor
sequenc
pointofcar
clinic
sequenc
applic
mng
test
done
patient
bedsid
emerg
room
local
clinic
field
importantli
select
sequenc
pathogen
read
demonstr
nanopor
platform
earli
termin
sequenc
human
read
identifi
real
time
although
attract
purpos
protect
patient
privaci
confidenti
human
read
deplet
part
sequenc
run
approach
current
scalabl
owe
limit
throughput
nanopor
sequenc
date
million
mng
read
per
run
minion
nanopor
sequenc
need
comput
match
read
refer
sequenc
real
time
autom
instrument
clinic
laboratori
enabl
parallel
process
mani
sampl
time
pointofcar
refer
diagnost
test
medic
procedur
done
near
time
place
patient
care
exampl
bedsid
emerg
depart
developingworld
field
laboratori
cluster
densiti
illumina
sequenc
system
qualiti
control
metric
refer
densiti
clonal
cluster
produc
cluster
correspond
singl
read
optim
cluster
densiti
need
maxim
number
accuraci
read
gener
sequenc
run
wwwnaturecomnrg
june
volum
partial
mitig
increas
sequenc
depth
per
sampl
cost
continu
drop
comprehen
sive
direct
detect
method
mng
may
eventu
replac
cultur
antigen
detect
pcr
method
clinic
microbiolog
indirect
approach
viral
serolog
test
continu
play
key
part
diagnost
work
infect
function
assay
cultur
phenotyp
suscept
test
ing
like
alway
use
research
studi
summari
current
limit
suggest
mng
unlik
replac
convent
diagnost
short
term
complementari
perhap
essenti
test
certain
clinic
situat
although
use
mng
inform
clinic
care
demonstr
multipl
case
report
small
case
seri
nearli
studi
retro
spectiv
clinic
util
yet
establish
larg
scale
prospect
clinic
trial
prospect
clinic
studi
critic
understand
perform
mng
diagnost
yield
compar
method
exampl
mng
transcrip
tomic
approach
might
enabl
effect
treatment
triag
wherebi
antimicrobi
need
patient
show
infecti
profil
gene
express
non
infecti
profil
treat
caus
particular
prospect
clinic
trial
econom
data
show
cost
effect
rel
expens
test
improv
patient
outcom
need
justifi
use
data
also
sup
port
pathway
toward
regulatori
approv
clini
cal
reimburs
high
qualiti
evid
clinic
metagenom
assay
effect
guid
patient
manag
requir
protocol
minim
potenti
assay
patient
select
bia
compar
relev
health
outcom
use
data
set
gener
larg
patient
cohort
predict
next
year
prospect
clinic
trial
data
evalu
clinic
util
cost
effect
mng
becom
avail
overal
cost
turnaround
time
mng
continu
drop
aspect
mng
beyond
mere
identifica
tion
incorpor
human
host
respons
microbiom
data
prove
clinic
use
robot
sampl
handl
microfluid
devic
devel
ope
push
button
oper
comput
analysi
platform
wide
avail
local
cloud
obviat
need
dedic
bioinfor
matic
expertis
least
mng
base
diag
nostic
assay
infecti
diseas
attain
regulatori
approv
clinic
reimburs
wit
widespread
democrat
mng
genom
analys
becom
wide
access
physician
research
also
patient
public
via
crowdsourc
initi
furthermor
world
constantli
emerg
pathogen
envisag
mng
base
test
pivot
role
monitor
ing
track
new
diseas
outbreak
surveil
network
rapid
diagnost
platform
nano
pore
sequenc
deploy
global
possi
ble
detect
contain
infecti
outbreak
much
earlier
stage
save
live
lower
cost
near
futur
mng
luxuri
necess
clinician
armamentarium
engag
perpetu
fight
infecti
diseas
qscore
qualiti
control
metric
dna
sequenc
logarithm
relat
base
call
error
probabl
serv
measur
read
accuraci
method
evalu
perform
individu
laboratori
specif
laboratori
test
use
standard
set
unknown
sampl
permit
interlaboratori
comparison
sequenc
method
dna
rna
molecul
transport
miniatur
pore
electrophoresi
